Anti-TIGIT antibodies have demonstrated promising results in boosting immune responses, particularly when combined with other immune checkpoint inhibitors, such as PD-1/PD-L1 blockers. These ...

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...